Skip to main content

Find Clinical Trials

Home
Conditions
Refractory Multiple Myeloma

Clinical trial condition

Refractory Multiple Myeloma

Explore clinical trials studying Refractory Multiple Myeloma. Study availability and eligibility vary by location and protocol.

155 public trials 23 recruiting studies

Refine in advanced search Browse all conditions

Refractory Multiple Myeloma trial results

Completed

Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies

NCT01273766

Conditions: Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, +206 more
Locations: Comprehensive Cancer Center of Wake Forest University Winston-Salem, North Carolina, United States

View Trial Details

Completed

Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer

NCT01053494

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Amyloidosis, +170 more
Locations: Wake Forest University Health Sciences Winston-Salem, North Carolina, United States

View Trial Details

Completed

AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma

NCT01129193

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, +118 more
Locations: The Ohio State University James Cancer Hospital Columbus, Ohio, United States

View Trial Details

Completed

Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma

NCT01083602

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +19 more
Locations: University of California at Los Angeles Los Angeles, California, United States

Stanford University Medical Center Division of Hematology Stanford, California, United States

H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida, United States

Emory University School of Medicine/Winship Cancer Institute Dept. of Winship Cancer Inst. Atlanta, Georgia, United States

View all 13 locations

View Trial Details

Completed

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

NCT02103335

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +18 more
Locations: University of Chicago Medical Center Chicago, Illinois, United States

University of Maryland Baltimore, Maryland, United States

Dana Farber Cancer Institute Boston, Massachusetts, United States

Karmanos Cancer Center Detroit, Michigan, United States

View Trial Details

Completed

Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT00054353

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States

University of Torino Torino, Italy

View Trial Details

Completed

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma

NCT00006244

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
Locations: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Completed

Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients

NCT01653106

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Digestive System Diseases, +22 more
Locations: Ohio State University Medical Center Columbus, Ohio, United States

View Trial Details

Completed

Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant

NCT00182663

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
Locations: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Completed

Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib

NCT01775553

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: Icahn School of Medicine at Mount Sinai New York, United States

View Trial Details